Antonin Rigaudière’s Post

🚀 Third Arc Bio Launches with $165M Series A to Revolutionise Biologics! 🧬💉 Third Arc Bio has successfully secured an oversubscribed $165 million Series A financing! This significant investment will fuel the development of superior biologics targeting solid tumors and inflammatory & immunology (II) diseases. 🔹 Key Highlights: -Strong Investor Support: The Series A round was led by premier biotech investors, underscoring confidence in Third Arc Bio's innovative approach. -Focus on Breakthrough Therapies: Third Arc Bio aims to advance biologics that offer enhanced efficacy and safety profiles for patients suffering from hard-to-treat conditions. -Expert Leadership: The company is led by a team of seasoned professionals with a proven track record in biotech and drug development. 🗣 Quote from the CEO: "We are excited to embark on this journey to deliver next-generation biologics that address significant unmet medical needs. Our team's expertise and the strong support from our investors will be crucial in bringing these transformative therapies to patients." — Peter Lebowitz 🌐 About Third Arc Bio: Third Arc Bio is committed to pushing the boundaries of biologics to improve patient outcomes in oncology and immunology. The company's cutting-edge research and development efforts are poised to make a substantial impact in the biotech industry. #Biotech #HealthcareInnovation #SeriesAFunding #ThirdArcBio #Oncology #Immunology #Biologics #Investment #Pharma #MedicalResearch #InnovationInMedicine

𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐃𝐫𝐮𝐠𝐬: 𝐓𝐫𝐞𝐧𝐝𝐬, 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 & 𝐅𝐮𝐭𝐮𝐫𝐞 𝐏𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐬 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐆𝐮𝐢𝐝𝐞: https://lnkd.in/d7ScBhs4 The oncology drugs market is seeing unprecedented growth, driven by increasing cancer cases, innovations in targeted therapies, and strong demand for personalized treatments. Valued at $221.38 billion in 2023, it's projected to grow rapidly, reaching an impressive $525.08 billion by 2031! 📈 What’s fueling this momentum? 1️⃣ Precision Medicine: Treatments are becoming more targeted, enhancing efficacy while minimizing side effects. 2️⃣ Immuno-Oncology: Immune-based therapies are providing new hope, leveraging the body's immune system to fight cancer. 3️⃣ Innovation & Tech: AI and machine learning are fast-tracking drug discovery and clinical trials, bringing novel drugs to market faster. 4️⃣ Global Investments: Both public and private sectors are heavily investing in oncology R&D, leading to the creation of innovative and accessible therapies. 🌐 Challenges and Opportunities While the growth is promising, the industry faces hurdles like high development costs, regulatory complexities, and pricing pressures. Yet, the potential for groundbreaking discoveries and patient impact keeps this market at the forefront of pharmaceutical advancements. 🔍 Major Players Analysis Listed in this Report are: Amgen Bayer Celgene GSK ARIAD Pharmaceuticals, Inc. Eli Lilly and Company Novartis Hoffmann-La Roche Ltd. AstraZeneca Boehringer Ingelheim Pfizer Teva Pharmaceuticals #CancerTreatment #OncologyMarket #PrecisionMedicine #Pharmaceuticals #DrugDiscovery #HealthcareInnovation #OncologyDrugs #ImmunoOncology #CancerResearch #MedicalAdvancements #PharmaIndustry #LifeSciences #OncologyNews #HealthTech

Fresh news sells best. I invite you to fresh bites straight from hot San Diego. 1️⃣ Another big pharma representatives are looking for companies to acquire. Shortly after #BIO2024, GSK announced the acquisition of Elsie Biotechnologies. Elsie is a private #biopharma company dedicated to unlocking the full potential of oligonucleotide therapeutics. This acquisition allows to integrate oligonucleotide discovery, synthesis, and delivery technologies to enhance GSK’s platform R&D capabilities. 2️⃣ AstraZeneca is expanding its oncology portfolio. Through the acquisition of Fusion Pharmaceuticals, including their most advanced program, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), it brings new expertise and capabilities in R&D, manufacturing and supply chain for #radioconjugates. 3️⃣ Moderna's vaccine was approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. The RSV vaccine is the first mRNA-based #vaccine that does not contain COVID-19 virus. Moderna expects mRESVIA to be commercially available before the 2024/2025 respiratory virus season. 4️⃣ Expanding capabilities is another milestone for Mabion S.A. One of the leading CDMO companies in Europe has almost doubled its manufacturing capacity due to the demand from companies for processing capacity in the field of #biologics. 5️⃣ During the BIO International Convention, several panel discussions and sessions focused on the use of AI tools in #biotech. I was particularly impressed by the opinions presented by CerFlux and CGI. A huge thank you for the insight goes to Andy F., who imparted a wealth of knowledge about data management, business analytics and implementing new technologies into companies. I also thank Karim Budhwani for developing an in vitro, ex vivo and in silico platform for cancer modeling and precision and personalized #oncology.

Biogen's Billion Dollar Bet: Can This Antibody Be a Pipeline in a Product? 5 Key Points for Investors on Biogen's Acquisition of HI-Bio: 1) Diversification Play: Biogen is heavily invested in neuroscience, and CEO Chris Viehbacher sees this as a risk. Buying HI-Bio allows Biogen to expand into immunology, a growing market with promising potential. 2) Promising Late-Stage Asset: The key driver here is felzartamab, an anti-CD38 monoclonal antibody entering phase 3 trials for multiple rare immune-mediated diseases. Early data shows positive impact on biomarkers and clinical endpoints in kidney diseases with significant unmet needs. 3) Pipeline-in-a-Product Potential: Felzartamab's ability to target various diseases (PMN, AMR, IgAN, potentially lupus) creates a broad development program. If successful, Biogen gains a significant foothold in immunology with a single platform. 4) Leveraging Expertise: Biogen plans to utilize its existing capabilities in rare disease development and commercialization for felzartamab. They also aim to retain HI-Bio's talent and establish an immunology team in the San Francisco Bay Area. 5) Bonus Asset: Beyond felzartamab, Biogen acquires a phase 1 anti-C5aR1 antibody for complement-mediated diseases, adding further value to the deal. My take: This acquisition looks like a strategic move for Biogen to lessen its dependence on neuroscience and enter the high-growth immunology space. Felzartamab's potential across multiple rare diseases is particularly exciting, but success hinges on phase 3 clinical trials. Investors should carefully monitor these trials and the overall integration of HI-Bio's assets into Biogen's pipeline. As an investor, what do you think about this diversification move? Leave your comments below. Share this news with your investor buddies. They’ll thank you later. 🗣️ #biotech #investment #investor #vc #drug #healthcare #market #business #immunology #acquisition #pharmaceutical #company #innovation _________________________________________________________________________________ Biotech investor or innovator? We assist investors unlock potential by assisting with due diligence and companies refine strategies for success and get bigger exposure to investors. Send me a DM and let´s connect Follow me, hit the 🔔 Adrian Rubstein

📢 Calling companies and potential partners working in #oncology! Are you attending #BioTrinity 2024 in the City of London this week? A team from our Business and Innovation Office will be there to speak to possible partners, collaborators and funders about opportunities to work with us across a broad portfolio of our cancer research. As one of the top-rated UK academic organisations in industry collaboration, we currently work with around 100 commercial partners to develop our discoveries into new cancer treatments. Highlights in the past year include the Food and Drug Administration (FDA) approval of breast cancer drug capivasertib (now branded Truqap), which was discovered by AstraZeneca following a long-running collaborative research programme also including Astex Pharmaceuticals. 🤝 Come and meet our team at BioTrinity (Ceri Mathews, Joo-Hee Sir, Jennifer Hodgson and Jonathan Beech) to discuss partnering with us, or joining our network of VCs and potential investors. If you are already registered to attend BioTrinity 2024, you can set up a meeting via the link 👇 https://lnkd.in/eD8baaQZ #CancerResearch #Commercialisation #TechTransfer #LifeSciences #BioTech #Pharmaceutical #TechnologyTransfer #University #Academia #Industry #StartUp #Technology #Innovation #BioTechnology #Pharma #Biology #Medicine #Health #PharmaIndustry #IndustryCollaboration

🌟 Exploring the Future of the Monoclonal Antibodies Market 🌟 https://lnkd.in/dGWvA7sh As someone deeply involved in the healthcare industry, I've seen firsthand how monoclonal antibodies (mAbs) are transforming patient care. With applications in cancer, autoimmune diseases, and infectious diseases, these targeted therapies offer a beacon of hope for many. 💡 Here’s what excites me about the future of mAbs: Innovation at its Core: Advances in biotechnology are enabling the development of more effective and safer mAbs. The precision with which they target specific cells is revolutionizing treatment protocols. Expanding Applications: Beyond cancer, mAbs are finding their way into treatments for conditions like rheumatoid arthritis, multiple sclerosis, and even COVID-19. This versatility is expanding the market and driving growth. Novartis, Pfizer, GSK, Amgen, Merck & Co., Inc., Daiichi Sankyo US, Abbott, AstraZeneca, Eli Lilly and Company, Johnson & Johnson MedTech #Healthcare #Biotechnology #MonoclonalAntibodies #Innovation #PersonalizedMedicine #Pharma #LifeSciences

👇 𝐓𝐡𝐞𝐬𝐞 𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐭𝐨𝐩 𝟓 𝐧𝐞𝐰𝐬 𝐬𝐭𝐨𝐫𝐢𝐞𝐬 𝐚𝐫𝐨𝐮𝐧𝐝 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐲𝐨𝐮 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐝 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤 👇 1️⃣ Novo Holdings, a leading life science investor, has invested £50 million in Oxford Nanopore Technologies, a UK-based company known for its advanced molecular sensing technology. The investment highlights confidence in Oxford Nanopore’s potential in the biopharmaceutical sector. 📰 https://lnkd.in/eEpFY6ep 2️⃣ GSK and Flagship Pioneering have announced a collaboration, committing $150 million to explore potential respiratory and immunology programs. This partnership aims to develop up to 10 novel medicines and vaccines, with GSK holding exclusive rights for further development. The deal could result in up to $7.2 billion in milestone payments if all programs succeed, although this is unlikely given the high failure rate in drug development. 📰 https://lnkd.in/eWm3Eztt 3️⃣ Roche, through its Genentech arm, has licensed Sangamo Therapeutics’ gene repression technology targeting the tau protein, believed to be a key driver of Alzheimer’s disease. The deal, valued at nearly $2 billion, includes $50 million upfront with the potential for significant milestone payments. This collaboration focuses on developing genomic medicines for neurodegenerative diseases, leveraging Sangamo’s zinc finger molecules and novel delivery methods to overcome challenges in treating brain conditions. 📰 https://lnkd.in/eNQYWtK9 4️⃣ Jade Biosciences, a biotech company focused on developing therapies for autoimmune diseases, secured $80 million in funding. The investment will support the development of targeted biologics aimed at unmet medical needs in inflammation and immunology. 📰 https://lnkd.in/eF9xya2k 5️⃣ NorthStar Medical Radioisotopes and Convergent Therapeutics have expanded their collaboration for CONV01-α, a prostate cancer therapy. This partnership involves NorthStar providing high-purity Ac-225, a key component in the treatment, and manufacturing the drug for clinical trials. 📰 https://lnkd.in/eRJgw7SP #FinancialDevelopments #LifeSciences #NewsRoundUp

The conclusion of January marks a period of notable M&A endeavors in the industry. In 2023, global life sciences M&A expenditure surged to US$191 billion, indicating a substantial 34% increase from the previous year. The resurgence of major pharmaceutical companies notably contributed to this uptick, propelling the average deal size worldwide by an impressive 77%. Some notable activity from January: Basking Biosciences Inc Biosciences: Raised $55 million led by ARCH Venture Partners for clinical development of BB-031, targeting von Willebrand Factor for acute ischemic stroke treatment. Cour Pharmaceuticals Development Co., Inc.: Secured $105 million in Series A with participation from Roche Venture Fund, Pfizer Breakthrough Growth Initiative, and Bristol Myers Squibb for immune-mediated disease therapies. Synnovation Therapeutics: Raised $102 million in Series A to develop cancer drugs, with a lead molecule SNV1521 showing promise in preclinical tests. Calluna Pharma: Merged Oxitope Pharma and Arxx Therapeutics, securing €75 million for selective antibody pipeline targeting inflammatory and fibrotic diseases. Accent Therapeutics, Inc. : Received $75 million in Series C for RNA drug development, focusing on DHX9 and KIF18A targets, aiming for human trials before the year-end. Comanche Biopharma: Raised $75 million in Series B led by GV to advance preeclampsia treatment CBP-4888, targeting sFlt1 protein overproduction. Ratio Therapeutics: Secured $50 million in Series B with Bristol Myers Squibb as a new investor for radiopharmaceutical platforms and lead asset targeting FAP. Tr1X : Emerged with $75 million in Series A to develop regulatory T-cell-based therapies for inflammation and immunology diseases. Lykos Therapeutics (formerly MAPS PBC): Raised $100 million for psychedelic and chemical analog therapeutics, the group also rebranded from MAPS PBC. Claris Bio: Secured $57 million in Series A to develop CSB-001 for corneal disease treatment. Moonwalk Biosciences: Received $57 million in Series A to develop epigenetic medicines targeting the epigenetic code. HI-Bio: Raised $95 million in Series B for therapeutic candidate felzartamab targeting CD38 and HIB210 for neutrophil activation and chemotaxis. Radionetics Oncology: Secured $52.5 million in Series A to develop radiopharmaceuticals targeting novel GPCRs for cancer treatment, with Paul Grayson as CEO. #MergersAndAcquisitions #LifeSciences #Investment #Funding #Biotech #Pharmaceuticals #ClinicalDevelopment #ImmuneTherapies #CancerResearch #Antibodies #RNA #DrugDevelopment #Preeclampsia #Radiopharmaceuticals #Psychedelics #Therapeutics #CornealDisease #Epigenetics #RegulatoryTCells #Inflammation #Immunology #GlobalHealth #HealthcareInvestment

🚀 Top 4 Global Pharma Giants: Leading the Future of Healthcare🌍 The pharmaceutical landscape is constantly evolving, with a few key players driving innovation and shaping global healthcare. Here are the top four pharma companies that continue to lead the way: 1. Pfizer: Known for its pioneering mRNA technology, Pfizer's COVID-19 vaccine highlighted its commitment to innovation. The company continues to expand in oncology, immunology, and cardiovascular treatments. 2. Roche: As a biotech leader, Roche excels in oncology and personalized medicine. Their diagnostics division also played a critical role during the pandemic. 3. Johnson & Johnson: With a diverse portfolio spanning pharmaceuticals, medical devices, and consumer health, J&J is a dominant force. Its contributions in oncology and its one-shot COVID-19 vaccine cemented its global influence. 4. Novartis: A frontrunner in oncology and gene therapies, Novartis focuses on cutting-edge treatments like CAR-T cell therapies, leading the charge in precision medicine. These companies have solidified their positions through continuous investment in R&D, breakthrough therapies, and a commitment to addressing unmet medical needs. Their efforts are driving the future of healthcare worldwide. 🌱💉 #Pharma #HealthcareInnovation #Biotech #Pfizer #Roche #JohnsonAndJohnson #Novartis #GlobalHealth #PrecisionMedicine #R&D #NIPER #Pharmaindustry #cancer #d2d